1 Abstract
We developed a network-based SEIRV model to test different vaccine efficacies on SARS-CoV-2 dynamics in a naive population of 25,000 susceptible adults. Different vaccine efficacies, derived from data, were administered at different rates across a range of different Watts-Strogatz network structures. The model suggests that differences among vaccines were of minor importance compared to vaccination rates and network structure. Additionally, we tested the effect of strain differences in transmissibility (R0 values of 2.5 and 5.0) and found that this was the most important factor influencing the number of individuals ultimately infected. However, network structure was most important in affecting the maximum number of individuals that were infectious during the epidemic peak. The interaction of network structure, vaccination effort, and difference in strain transmissibility was highly significant for all epidemic metrics. The model suggests that differences in vaccine efficacy are not as important as vaccination rate in reducing epidemic sizes. Further, the importance of the evolution of viral transmission rates and our ability to develop effective vaccines to combat these strains will be of primary concern for our ability to control future disease epidemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All computer code produced in the present study are available upon reasonable request to the authors
